Hans Edgar Bishop
CIK 1480212 · CEO & President · last filed 2026-10-06
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
JUNO price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SUITE 400
SEATTLE, WA 98102
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| SANA | Director | 5,863,480 | $2.38 | $13.93M | $0 | 28 | 2026-10-06 |
| LYEL | Director | 234,281 | $9.48 | $2.22M | $0 | 7 | 2024-06-17 |
| A | Director | 24,226 | $173.25 | $4.20M | $0 | 9 | 2024-03-19 |
| CELGENE CORP /DE/ (CELGZ) Delisted | Director | 0 | — | — | $0 | 3 | 2019-11-22 |
| Juno Therapeutics, Inc. (JUNO) Delisted | CEO & President | 135,452 | — | — | -$34.48M | 17 | 2018-03-07 |
| AVANIR PHARMACEUTICALS, INC. (AVNR) Delisted | Director | 93,350 | — | — | $0 | 3 | 2014-02-14 |
Recent Filings · Page 3 of 8
73 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-07-06 | SANA | Grant (A) | +4,152 | $0 | EDGAR |
| 2023-06-20 | LYEL | Grant (A) | — | $0 | EDGAR |
| 2023-06-09 | SANA | Grant (A) | — | $0 | EDGAR |
| 2023-04-06 | SANA | Grant (A) | +7,716 | $0 | EDGAR |
| 2023-03-20 | A | Grant (A) | +2,399 | $328.2K | EDGAR |
| 2023-01-06 | SANA | Grant (A) | +6,702 | $0 | EDGAR |
| 2022-10-06 | SANA | Grant (A) | +4,012 | $0 | EDGAR |
| 2022-09-09 | LYEL | Exer (M) | +145,380 | $14.5K | EDGAR |
| 2022-07-07 | SANA | Grant (A) | +3,328 | $0 | EDGAR |
| 2022-06-10 | LYEL | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.